TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9782681
Drug: CNS prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylactic chemotherapy
Study: 2905187
Drug: Fraxiparin (7500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparin (7500 anti-Xa units, once daily)
Study: 2905187
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5000 units, three times daily)
Study: 12528545
Drug: Total flavones
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total flavones of Hippophae rhamnoides L. (TFH)
Study: 12528545
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist nifedipine
Study: 31680083
Drug: 1% amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% amitriptyline gel
Study: 31680083
Drug: Standard conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conventional treatment
Study: 29481765
Drug: ASSIST-linked brief
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASSIST-linked brief intervention (10-step BI) for illicit drug use
Study: 22763801
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg for weeks 1-4, 40 mg for weeks 5-8
Study: 22763801
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (LOS) 50 mg for weeks 1-4, 100 mg for weeks 5-8
Study: 11907289
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a minimum of 12 weeks
Study: 11907289
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 4 weeks followed by 250 mg twice daily for a minimum of 12 weeks
Study: 11907289
Drug: Bosentan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (both doses)
Study: 30392864
Drug: Cognitive-behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral and motivational interviewing family-based weight loss treatment
Study: 28237048
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment PDD (weeks 1‐7)
Study: 25492848
Drug: Isosorbide-5-mononitrate (5-ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fasting conditions
Study: 25492848
Drug: Isosorbide-5-mononitrate (5-ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fed conditions
Study: 19500381
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (500 mg iron polymaltose, single dose)
Study: 19500381
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (2 ferrous sulphate slow-release tablets daily)
Study: 6391157
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily for three weeks)
Study: 29409728
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) treatment
Study: 21056314
Drug: Microdose GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microdose GnRH agonist flare (MF)
Study: 21056314
Drug: GnRH antagonist/letrozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH antagonist/letrozole
Study: 12042457
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of vitamin B-6
Study: 3142984
Drug: Parenteral lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral lipid infusion (IL) (Vitrum)
Study: 3142984
Drug: No parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No parenteral lipid infusion (NL)
Study: 26479162
Drug: Hydrocodone/Acetaminophen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/Acetaminophen (5 mg/325 mg)
Study: 24521629
Drug: Niacin 750
Normalized name: niacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 750 mg/day
Study: 24521629
Drug: Niacin 1500
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 1500 mg/day
Study: 24521629
Drug: Fenofibrate 320
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 320 mg/day
Study: 19162468
Drug: Phenylephrine (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (40-120 microg, administered as intermittent i.v. bolus)
Study: 17204681
Drug: Anticoagulants (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (unfractionated heparin or low‐molecular‐weight heparin or heparinoids)
Study: 11257244
Drug: Alcohol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.4 g/kg p.o., approximately 2‐3 standard drinks)
Study: 11257244
Drug: Controlled alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled alcohol intake (0.8 g/kg/day)
Study: 9444594
Drug: LD-PDGF/IGF-I (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-PDGF/IGF-I (50 micrograms/ml each of rhPDGF-BB and rhIGF-I in a gel vehicle)
Study: 9444594
Drug: HD-PDGF/IGF-I (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-PDGF/IGF-I (150 micrograms/ml each of rhPDGF-BB and rhIGF-I plus vehicle)
Study: 7524312
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid antibody testing for hepatitis C
Study: 3226754
Drug: High-Dosage Regimen
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dosage Regimen (HDR; n = 51) - NS 550 mg every 8 h for 3 days
Study: 3226754
Drug: Low-Dosage Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dosage Regimen (LDR; n = 49) - Initial dose of NS 550 mg followed by NS 275 mg every 8 h through day 3
Study: 4132247
Drug: FSH/LH-RH treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH/LH-RH treatment
Study: 28103841
Drug: Usual Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual Nicotine Content (11.6 mg)
Study: 28103841
Drug: Reduced Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Nicotine Content (progressively reduced from 11.6 mg to 0.2 mg)
Study: 26252522
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg (NMBA group)
Study: 21237635
Drug: Manual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual and manipulative therapy (MMT)
Study: 7879405
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (control)
Study: 31891824
Drug: Any dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any dose as wP
Study: 23845010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of universal and selective interventions
Study: 20482894
Drug: Accelerated hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hand BMD loss (>‐0.003 g/cm2) in the first year of RA
Study: 20482894
Drug: Anti-citrullinated protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-citrullinated protein antibody positivity
Study: 16210834
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 2.5 mg (n = 79)
Study: 16210834
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 5 mg (n = 77)
Study: 16210834
Drug: Tibolone of
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone of 2.5 mg (n = 76)
Study: 16210834
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (Ca) of 1,000 mg (n = 54)
Study: 10323625
Drug: Pseudoephedrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (1 mg/kg body weight)
Study: 1908584
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg PO)
Study: 29862491
Drug: 0.5% colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% colchicine cream
Study: 21203389
Drug: IST and
Normalized name: Wrist and Arm Immobilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IST and treatment with SP
Study: 21203389
Drug: IST and
Normalized name: Wrist and Arm Immobilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IST and treatment with AQ+AS
Study: 11948271
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir and Oral valganciclovir
Study: 10451813
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta‐estradiol
Study: 10451813
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol
Study: 8519718
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Study: 8519718
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Study: 2130290
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg phenobarbital
Study: 2130290
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg phenobarbital
Study: 28669962
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Study: 28669962
Drug: Dexmedetomidine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.50 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Study: 28669962
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Study: 17719702
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched products (20 g low-fat margarine and 250 ml low-fat milk delivering 2.3g plant sterols/d)
Study: 15601557
Drug: Intratumoral H101
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral H101 injection combined with PF regimen (cisplatin + 5-fluorouracil)
Study: 15601557
Drug: Intratumoral H101
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral H101 injection combined with AF regimen (adriamycin + 5-fluorouracil)
Study: 9551737
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg at 30 L x min[‐1]
Study: 9551737
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg at 90 L x min[‐1]
Study: 9551737
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at 30 L x min[‐1]
Study: 9551737
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at 90 L x min[‐1]
Study: 7020917
Drug: R.T. plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: R.T. plus L-PAM
Study: 28730328
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine patch (5, 10, 15, and 20 μg/h)
Study: 28730328
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol (150, 200, 250, and 300 mg)
Study: 19777852
Drug: Dachaihu soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dachaihu soup once daily for 7 days
Study: 18085153
Drug: Acup-moxibustion plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acup-moxibustion plus western medicine
Study: 9370106
Drug: Exogenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous GLP-1 (administered i.v. or s.c.)
Study: 4011640
Drug: 0.66 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.66 ml/kg of body weight
Study: 4011640
Drug: 1.2 ml/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 ml/l of total body water
Study: 31325345
Drug: 17% watery
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% watery solution of glycerol
Study: 26778329
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab treatment for CME
Study: 22380577
Drug: Bisphosphonates (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (weekly alendronate/risedronate)
Study: 20215101
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of search by story topic and writer profile
Study: 17921395
Drug: Custards containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custards containing 20 g cooked acetylated high‐amylose maize starch (HAMSA)
Study: 17921395
Drug: Custards containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custards containing 20 g cooked propionylated high‐amylose maize starch (HAMSP)
Study: 17921395
Drug: Custards containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custards containing 20 g cooked butyrylated high‐amylose maize starch (HAMSB)
Study: 16160589
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg doxazosin/d
Study: 16160589
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg doxazosin/d
Study: 11865965
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day synthetic conjugated estrogens (n = 35)
Study: 10075186
Drug: Treatment videotape
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment videotape
Study: 7728980
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of 300 g of cooked Brussels sprouts per day for 1 week
Study: 1922194
Drug: Amorolfine 50
Normalized name: amorolfine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 50 mg
Study: 1922194
Drug: Amorolfine 100
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 100 mg
Study: 1922194
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg
Study: 6348177
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg acyclovir intravenously three times daily
Study: 24861583
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g acetazolamide
Study: 18204148
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg/day, n=30)
Study: 16354891
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (triphasic ethinyl estradiol 35 microg + norethindrone 0.5 to 1 mg for 12 cycles of 28 days)
Study: 8018766
Drug: Interferon-alpha (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (alpha n-1 IFN) treatment at a dosage of 3 MU/day subcutaneously for 5 months
Study: 31721277
Drug: Otaplimastat 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otaplimastat 80 mg (administered twice daily for 3 days)
Study: 31721277
Drug: Otaplimastat 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otaplimastat 40 mg
Study: 31721277
Drug: Otaplimastat 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otaplimastat 80 mg
Study: 11832440
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and pentagastrin
Study: 10412851
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg amoxicillin plus 125 mg clavulanic acid (Augmentin), every 8 h for 10 days
Study: 2321778
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl
Study: 2321778
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl plus 3.33 micrograms/ml epinephrine
Study: 2321778
Drug: Lidocaine test
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine test dose
Study: 2321778
Drug: 2-chloroprocaine test
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-chloroprocaine test dose
Study: 7192498
Drug: Serum antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antibodies to cow milk proteins
Study: 7192498
Drug: Serum antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antibodies to soy protein
Study: 31921170
Drug: GTU®MultiHIV DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTU®MultiHIV DNA vaccine delivered by transcutaneous (TC) and intramuscular (IM) injection
Study: 25439415
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 1 mg/kg
Study: 23213984
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (n=26)
Study: 20371164
Drug: L-alanyl-glutamine (l-Ala-Gln)
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-glutamine (l-Ala-Gln)
Study: 7719880
Drug: Bricanyl Turbuhaler
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bricanyl Turbuhaler (terbutaline sulphate 0.5 mg t.i.d.)
Study: 7719880
Drug: Ventolin Rotahaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin Rotahaler (salbutamol 0.4 mg t.i.d.)
Study: 2126657
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg after cord clamping
Study: 7341284
Drug: Sotalol and
Normalized name: sotalol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol and Metoprolol (combined with thiazide diuretic)
Study: 25656999
Drug: Peanut sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut sublingual immunotherapy (SLIT)
Study: 24724774
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein as a supplement without dietary modification (WPS)
Study: 22494623
Drug: L-BLP25
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BLP25
Study: 19397502
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.5% bupivacaine
Study: 19397502
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.25% bupivacaine
Study: 16170977
Drug: 2.5% lidocaine/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine/2.5% prilocaine (L/P)
Study: 12240780
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg PO or IV q24h
Study: 12240780
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg IV q24h for > or = 2 days plus ceftriaxone 1 g IV q24h for 2 days
Study: 10422936
Drug: Neostigmine/glycopyrrolate (0.05/0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine/glycopyrrolate (0.05/0.01 mg/kg)
Study: 7818126
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L unhumidified O2 via nasal cannula
Study: 2204260
Drug: Trapidil 300
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil 300 mg/day (TT group)
Study: 23424215
Drug: Caffeine at
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine at 250 mg day(-1)
Study: 23424215
Drug: DMAA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAA at 50 mg day(-1)
Study: 23424215
Drug: Caffeine at
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine at 250 mg day(-1) + DMAA at 50 mg day(-1)
Study: 21376643
Drug: Heparin-bonded PTFE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded PTFE grafts (Hb-PTFE)
Study: 19304089
Drug: Topical mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mitomycin-C (MMC) 0.2 mg/mL applied for 45 seconds after PRK
Study: 19304089
Drug: Topical mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mitomycin-C (MMC)
Study: 17526168
Drug: Methycbal (Mecolbalamin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methycbal (Mecolbalamin) administration
Study: 10682136
Drug: Stavudine 20
Normalized name: stavudine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 20 mg twice daily
Study: 10682136
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg twice daily
Study: 10682136
Drug: Stavudine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (both doses)
Study: 8313315
Drug: FUDR (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUDR (0.3 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day continuous infusion through an implantable hepatic arterial pump alternating with a 4‐week rest period (Group D)
Study: 8313315
Drug: FUDR (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUDR (0.25 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day infusion alternating with 2 weeks of saline (Group E)